53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100042744 | 2021-02-01 | 2021-01-27 | To explore the value of serological, salivary and histological examinations in the diagnosis of Sjogren's syndrome | To explore the value of serological, salivary and histological examinations in the diagnosis of Sjogren's syndrome | Sjogren syndrome | Gold Standard:AECC standards proposed by the United States and European Union in 2020, including primary and secondary.;Index test:1. Serum ANA, anti-SSA /SSB antibody; 2. ultrasonography of salivary glands; 3. nuclide imaging of salivary glands; 4. Labial gland biopsy.; | Longyan First Affiliated Hospital of Fujian Medical University | NULL | Recruiting | Both | Target condition:60;Difficult condition:20 | China | |||
| 2 | ChiCTR2000035194 | 2020-10-01 | 2020-08-02 | The value of exosome miR29 for biomarker of primary Sjogren's syndrome with interstitial lung disease | The value of exosome miR29 for biomarker of primary Sjogren's syndrome with interstitial lung disease | Sjogren's syndrome; Interstitial lung disease | Gold Standard:According to the clinical manifestations, chest imaging (cell-like change, ground glass change, solid shadow, mesh shadow), lung ventilation and diffusion function (FVC, DLCO), pathological biopsy and the elimination of ILD caused by other known reasons. If necessary, a surgical lung biopsy is feasible.;Index test:miRNA-29; | Tongji Hosipital, Tongji University School of Medicine | NULL | Recruiting | 18 | Both | Target condition:60;Difficult condition:60 | China |